Compare Applied Materials, Inc. (AMAT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Applied Materials, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Applied Materials, Inc. trades at $537.5 (market cap $414.54B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Applied Materials, Inc. is far larger — about 232.9× Recursion Pharmaceuticals Inc's market cap, and Applied Materials, Inc. pays a 0.41% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMAT | RXRX | |
|---|---|---|
Market Cap | $414.54B | $1.78B |
Sector | Technology | Health |
52-Week High | $723.00 | $6.79 |
52-Week Low | $156.25 | $2.84 |
Enterprise Value | $413.57B | $1.30B |
Dividend Yield | 0.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Materials (AMAT) trades at $525.61, down 2.51% on the day, amid a neutral technical signal with key support at $510 and resistance at $546. The company shows strong fundamentals with a 29.31% net income margin and consistent earnings beats, including Q1 2026 EPS of $2.86 versus $2.68 expected. Recent news highlights CEO Gary Dickerson's optimism on AI-driven semiconductor demand, calling it the 'greatest time in the history of the industry' (CNBC, 2026-05-28).
Outlook remains positive with a consensus price target of $662.82, implying 26% upside, supported by 76.9% analyst buy ratings. Risks include high valuation multiples like a P/E of 49.12 and cyclical semiconductor equipment demand. The stock offers growth exposure to AI infrastructure but faces volatility from tech sector shifts.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
